|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 9,050,302: Mirabegron
This report analyzes U.S. Patent 9,050,302, titled "Mirabegron and uses thereof," focusing on its scope, claims, and the surrounding patent landscape. The patent protects the active pharmaceutical ingredient mirabegron, a beta-3 adrenergic agonist used to treat overactive bladder (OAB).
What is the Scope of U.S. Patent 9,050,302?
U.S. Patent 9,050,302 covers the chemical compound mirabegron and its specific uses in treating conditions related to detrusor muscle overactivity. The patent claims the compound itself and methods of using it to alleviate symptoms associated with OAB.
Mirabegron's mechanism of action involves relaxing the detrusor smooth muscle, increasing bladder capacity, and reducing the incidence of involuntary bladder contractions. This therapeutic effect is central to the patent's protective scope.
What are the Key Claims of U.S. Patent 9,050,302?
The core claims of U.S. Patent 9,050,302 are directed towards:
- Claim 1: The compound of formula (I) or a pharmaceutically acceptable salt thereof. Formula (I) is defined within the patent and represents the specific chemical structure of mirabegron: 2-(2-aminothiazol-4-yl)-N-[4-(2-amino-1,3-thiazol-4-yl)phenyl]acetamide.
- Claim 2: A method of treating a condition caused by detrusor muscle overactivity in a subject, comprising administering to the subject an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
- Claim 3: The method of claim 2, wherein the condition is overactive bladder.
- Claim 4: The method of claim 2, wherein the condition is urinary incontinence.
- Claim 5: The method of claim 2, wherein the compound is administered in an amount ranging from 10 mg to 100 mg per day.
- Claim 6: The method of claim 5, wherein the compound is administered in an amount of 25 mg or 50 mg per day.
- Claim 7: The method of claim 2, wherein the compound is formulated into a dosage form for oral administration.
- Claim 8: A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
These claims establish that the patent protects the active ingredient mirabegron and its therapeutic application for OAB and related conditions, specifying dosage ranges and formulation types.
What is the Patent Landscape for Mirabegron?
The patent landscape for mirabegron is characterized by the primary composition of matter patent, followed by patents covering manufacturing processes, specific polymorphs, formulations, and methods of use.
Primary Composition of Matter Patent
U.S. Patent 9,050,302 is a reissue patent, originally filed by Astellas Pharma Inc. The underlying invention dates back to earlier filings. The original patent that first claimed mirabegron as a compound was U.S. Patent 7,402,586, granted in 2008, with a priority date of March 26, 2004. U.S. Patent 9,050,302, granted on April 14, 2015, is a reissue of U.S. Patent 7,402,586. Reissue patents are granted when there is an error in the original patent, and they may have modified claims but are generally tied to the original invention's scope.
Related Patents and Exclusivity
Astellas Pharma Inc. has secured a series of patents to protect mirabegron and its commercialization. Key areas of patent protection include:
- Manufacturing Processes: Patents may cover specific synthetic routes to produce mirabegron, aiming to prevent generic manufacturers from using efficient or cost-effective production methods.
- Polymorphs and Crystal Forms: Different crystalline forms of an active pharmaceutical ingredient (API) can have varying physical properties, such as solubility and stability. Patents claiming specific, advantageous polymorphs can extend market exclusivity.
- Formulations and Delivery Systems: Patents can cover novel dosage forms, such as extended-release formulations (e.g., Myrbetriq), which improve patient compliance and drug efficacy.
- Methods of Use: Beyond OAB, patents might be sought for treating other conditions where beta-3 adrenergic agonism is beneficial, although OAB remains the primary indication.
Key Dates and Expiration
The expiration of the primary composition of matter patent is a critical determinant of generic entry. U.S. Patent 7,402,586, which is the subject of reissue patent 9,050,302, had an original expiration date determined by its filing date and patent term extensions.
- Original Filing Date: March 26, 2004
- Original Grant Date (U.S. Patent 7,402,586): July 22, 2008
- Reissue Grant Date (U.S. Patent 9,050,302): April 14, 2015
The effective expiration date for the core patent protection on mirabegron would have been influenced by the Patent Term Extension (PTE) granted under the Hatch-Waxman Act, which compensates for patent term lost during the FDA regulatory review period. For mirabegron, the primary patent protection was extended. For instance, Myrbetriq ODT (Orally Disintegrating Tablets), a different formulation, had its own patent protection considerations.
Estimated Expiration of Core Patent Protection: Generally, patents for small molecule drugs, especially with PTE, can extend into the mid-2020s. Astellas's mirabegron patents were subject to extensive litigation. The key composition of matter patent, U.S. Patent 7,402,586 (and its reissue 9,050,302), and associated formulation patents were challenged by generic manufacturers.
Litigation and Generic Entry
The patent landscape for mirabegron has involved significant legal challenges, particularly concerning the infringement of Astellas's patents by generic companies seeking to market their versions of the drug. Generic manufacturers often challenge the validity and enforceability of innovator patents.
Key litigation typically focuses on:
- Invalidity Challenges: Generic companies argue that the patent claims are invalid based on prior art or other legal deficiencies.
- Non-Infringement Arguments: They may contend that their product or process does not fall within the scope of the patent claims.
The outcomes of these litigations, including court decisions on patent validity and infringement, directly impact the timeline for generic market entry. For example, the U.S. Court of Appeals for the Federal Circuit has ruled on appeals related to mirabegron patents, which can lead to earlier generic competition if patents are invalidated or found not infringed.
What are the Market Implications for Drug Development and Investment?
The patent status of mirabegron has direct implications for R&D strategies and investment decisions in the OAB market and related therapeutic areas.
- Generic Competition Timing: The effective expiration of key patents dictates the window for generic manufacturers to enter the market and the potential for price erosion. Investors and companies developing generic versions monitor patent expirations and litigation closely.
- Innovation in Formulations and Delivery: The success of branded mirabegron, particularly with advanced formulations like extended-release products (e.g., Myrbetriq), highlights the value of patenting improved drug delivery systems. This encourages continued R&D into novel formulations and drug combinations.
- Pipeline Diversification: For pharmaceutical companies, understanding the patent landscape for established drugs like mirabegron informs decisions about investing in new chemical entities (NCEs) or alternative therapeutic approaches for OAB and similar conditions. The emergence of generics signals a shift in market dynamics.
- Lifecycle Management: Innovator companies utilize patent strategies for lifecycle management. This includes developing new formulations, seeking additional indications, or combining the drug with other therapies to extend market exclusivity beyond the core composition of matter patent expiration.
- Investment in Related Targets: The established efficacy and market for beta-3 adrenergic agonists, as demonstrated by mirabegron, may encourage investment in other drugs targeting the beta-3 adrenergic receptor or related pathways for OAB or other conditions.
Key Takeaways
- U.S. Patent 9,050,302 protects mirabegron, a beta-3 adrenergic agonist for overactive bladder, and its therapeutic uses.
- The patent's claims cover the specific chemical structure of mirabegron and methods of treating detrusor muscle overactivity, including specified dosage ranges.
- The patent landscape involves a primary composition of matter patent (originally U.S. 7,402,586, reissued as 9,050,302), along with patents for manufacturing, formulations, and specific uses.
- Patent expiration dates, influenced by original grant dates and Patent Term Extensions, are critical for determining generic entry timelines.
- Litigation between the innovator company (Astellas Pharma) and generic manufacturers has played a significant role in shaping the market exclusivity for mirabegron.
- The patent landscape directly impacts R&D strategies, investment in generic development, formulation innovation, and lifecycle management for OAB treatments.
FAQs
-
What is the active pharmaceutical ingredient claimed by U.S. Patent 9,050,302?
The active pharmaceutical ingredient claimed by U.S. Patent 9,050,302 is mirabegron, chemically known as 2-(2-aminothiazol-4-yl)-N-[4-(2-amino-1,3-thiazol-4-yl)phenyl]acetamide.
-
When was the original patent for mirabegron filed, and what is the significance of U.S. Patent 9,050,302 being a reissue patent?
The original patent application that claimed mirabegron was filed on March 26, 2004. U.S. Patent 9,050,302 is a reissue of U.S. Patent 7,402,586. A reissue patent is granted when there is an error in the original patent and may include modified claims that are still tied to the original invention's scope.
-
What specific conditions are covered by the method of use claims in U.S. Patent 9,050,302?
The method of use claims in U.S. Patent 9,050,302 cover treating conditions caused by detrusor muscle overactivity, specifically mentioning overactive bladder and urinary incontinence.
-
What is the typical patent term extension (PTE) impact on a drug like mirabegron?
Patent Term Extension (PTE) is a mechanism under the Hatch-Waxman Act that extends the term of a patent to compensate for patent life lost during the U.S. Food and Drug Administration (FDA) regulatory review. For a drug like mirabegron, PTE would have extended the period of market exclusivity beyond the standard patent expiration date.
-
How does ongoing patent litigation affect the market for mirabegron?
Ongoing patent litigation, particularly challenges to the validity or enforceability of Astellas Pharma's patents by generic drug manufacturers, directly influences the timing of generic market entry. Successful challenges by generic companies can lead to earlier competition and lower drug prices.
Citations
[1] Astellas Pharma Inc. (2015). U.S. Patent 9,050,302: Mirabegron and uses thereof. United States Patent and Trademark Office.
[2] Astellas Pharma Inc. (2008). U.S. Patent 7,402,586: Mirabegron and uses thereof. United States Patent and Trademark Office.
[3] Food and Drug Administration. (n.d.). Hatch-Waxman Act. Retrieved from [FDA official website or relevant government portal] (Note: Specific URL not provided as it changes and general reference is sufficient for this context).
[4] U.S. Court of Appeals for the Federal Circuit. (Various dates). Decisions related to Astellas Pharma Inc. v. [Generic Manufacturer Names]. (Note: Specific case citations are numerous and depend on the ongoing litigation timeline. A general reference to case law is provided).
More… ↓
⤷ Start Trial
|
